
2021 |
Stathis, C; Victoria, N; Loomis, K; Nguyen, SA; Eggers, M; Septimus, E; Safdar, N Review of the use of nasal and oral antiseptics during a global pandemic Artikel Future microbiology, 16 (2), S. 119-130, 2021. @article{Stathis.2021, title = {Review of the use of nasal and oral antiseptics during a global pandemic}, author = {C Stathis and N Victoria and K Loomis and SA Nguyen and M Eggers and E Septimus and N Safdar}, doi = {10.2217/fmb-2020-0286}, year = {2021}, date = {2021-01-01}, journal = {Future microbiology}, volume = {16}, number = {2}, pages = {119-130}, abstract = {A review of nasal sprays and gargles with antiviral properties suggests that a number of commonly used antiseptics including povidone-iodine, ListerinecircledR, iota-carrageenan~and chlorhexidine should be studied in clinical trials to mitigate both the progression and transmission of SARS-CoV-2. Several of these antiseptics have demonstrated the ability to cut the viral load of SARS-CoV-2 by 3-4 log10 in 15-30 s~in vitro. In addition, hypertonic saline targets viral replication by increasing hypochlorous acid inside the cell. A number of clinical trials are in process to study these interventions both for prevention of transmission, prophylaxis after exposure, and to diminish progression by reduction of viral load in the early stages of infection.}, keywords = {}, pubstate = {published}, tppubtype = {article} } A review of nasal sprays and gargles with antiviral properties suggests that a number of commonly used antiseptics including povidone-iodine, ListerinecircledR, iota-carrageenan~and chlorhexidine should be studied in clinical trials to mitigate both the progression and transmission of SARS-CoV-2. Several of these antiseptics have demonstrated the ability to cut the viral load of SARS-CoV-2 by 3-4 log10 in 15-30 s~in vitro. In addition, hypertonic saline targets viral replication by increasing hypochlorous acid inside the cell. A number of clinical trials are in process to study these interventions both for prevention of transmission, prophylaxis after exposure, and to diminish progression by reduction of viral load in the early stages of infection. |
Eggers, M; Schwebke, I; Suchomel, M; Fotheringham, V; Gebel, J; Meyer, B; Morace, G; Roedger, HJ; Roques, C; Visa, P; Steinhauer, K Euro Surveillance, 26 (3), S. pii=2000708., 2021. @article{Eggers.2021, title = {The European tiered approach for virucidal efficacy testing - rationale for rapidly selecting disinfectants against emerging and re-emerging viral diseases}, author = {M Eggers and I Schwebke and M Suchomel and V Fotheringham and J Gebel and B Meyer and G Morace and HJ Roedger and C Roques and P Visa and K Steinhauer}, doi = {10.2807/1560-7917.ES.2021.26.3.2000708}, year = {2021}, date = {2021-01-01}, journal = {Euro Surveillance}, volume = {26}, number = {3}, pages = {pii=2000708.}, abstract = {When facing an emerging virus outbreak such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a quick reaction time is key to control the spread. It takes time to develop antivirals and vaccines, and implement vaccination campaigns. Therefore, preventive measures such as rapid isolation of cases and identification and early quarantine of cases' close contacts-as well as masks, physical distancing, hand hygiene, surface disinfection and air control-are crucial to reduce the risk of transmission. In this context, disinfectants and antiseptics with proven efficacy against the outbreak virus should be used. However, biocidal formulations are quite complex and may include auxiliary substances such as surfactants or emollients in addition to active substances. In order to evaluate disinfectants' efficacy objectively, meaningful efficacy data are needed. Therefore, the European Committee for Standardisation technical committee 216 'Chemical disinfectants and antiseptics' Working Group 1 (medical area) has developed standards for efficacy testing. The European tiered approach grades the virucidal efficacy in three levels, with corresponding marker test viruses. In the case of SARS-CoV-2, disinfectants with proven activity against vaccinia virus, the marker virus for the European claim 'active against enveloped viruses', should be used to ensure effective hygiene procedures to control the pandemic.}, keywords = {}, pubstate = {published}, tppubtype = {article} } When facing an emerging virus outbreak such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a quick reaction time is key to control the spread. It takes time to develop antivirals and vaccines, and implement vaccination campaigns. Therefore, preventive measures such as rapid isolation of cases and identification and early quarantine of cases' close contacts-as well as masks, physical distancing, hand hygiene, surface disinfection and air control-are crucial to reduce the risk of transmission. In this context, disinfectants and antiseptics with proven efficacy against the outbreak virus should be used. However, biocidal formulations are quite complex and may include auxiliary substances such as surfactants or emollients in addition to active substances. In order to evaluate disinfectants' efficacy objectively, meaningful efficacy data are needed. Therefore, the European Committee for Standardisation technical committee 216 'Chemical disinfectants and antiseptics' Working Group 1 (medical area) has developed standards for efficacy testing. The European tiered approach grades the virucidal efficacy in three levels, with corresponding marker test viruses. In the case of SARS-CoV-2, disinfectants with proven activity against vaccinia virus, the marker virus for the European claim 'active against enveloped viruses', should be used to ensure effective hygiene procedures to control the pandemic. |
Kramer, A; Eggers, M; Hübner, N; Walger, P; Steinmann, E; Exner, M Virucidal gargling and virucidal nasal spray Artikel GMS Hygiene and Infection Control, 16 (Doc02), 2021, ISSN: 2196-5226. @article{Kramer.2021, title = {Virucidal gargling and virucidal nasal spray}, author = {A Kramer and M Eggers and N H\"{u}bner and P Walger and E Steinmann and M Exner}, doi = {10.3205/DGKH000373}, issn = {2196-5226}, year = {2021}, date = {2021-01-01}, journal = {GMS Hygiene and Infection Control}, volume = {16}, number = {Doc02}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
Greiner, J; Götz, M; Malner-Wagner, W; Wendt, C; Enders, M; Durst, C; Michel, D; von Harsdorf, S; Jung, S Cancer medicine, 10 (1), S. 237-246, 2021. @article{Greiner.2020, title = {Characteristics and mechanisms to control a COVID-19 outbreak on a leukemia and stem cell transplantation unit}, author = {J Greiner and M G\"{o}tz and W Malner-Wagner and C Wendt and M Enders and C Durst and D Michel and S von Harsdorf and S Jung}, doi = {10.1002/cam4.3612}, year = {2021}, date = {2021-01-01}, journal = {Cancer medicine}, volume = {10}, number = {1}, pages = {237-246}, abstract = {Immunosuppressed patients like patients with leukemia or lymphoma, but also patients after autologous or allogeneic stem cell transplantation are at particular risk for an infection with COVID-19. We describe a COVID-19 outbreak on our leukemia and stem cell transplantation unit (LSCT-Unit) originating from a patient with newly diagnosed acute myeloid leukemia. The patient was treated with intensive induction chemotherapy and we characterize the subsequent outbreak of COVID-19 on a LSCT-Unit. We describe the characteristics of the 36 contacts among the medical team, the results of their PCR and antibody tests and clinical aspects and features of infected employees. Of these 36 close contacts, 9 employees of the LSCT-Unit were infected and were tested positive by PCR and/or antibody-testing. 8/9 of them were symptomatic, 3/9 with severe, 5/9 with mild symptoms, and one person without symptoms. Due to stringent hygiene measures, the outbreak did not lead to infections of other patients despite ongoing clinical work. Moreover, we demonstrate that incubation period and clinical course of a COVID-19 infection in an immunosuppressed patient could be unusual compared to that of immunocompetent patients. Consistent PCR and antibody testing are helpful to understand, control, and prevent outbreaks. For the safety of health-care workers and patients alike, all employees wore FFP2 masks and were trained to adhere to several further safety guidelines. The implementation of rigorous hygiene measures is the key to controlling an outbreak and preventing infections of other patients.}, keywords = {}, pubstate = {published}, tppubtype = {article} } Immunosuppressed patients like patients with leukemia or lymphoma, but also patients after autologous or allogeneic stem cell transplantation are at particular risk for an infection with COVID-19. We describe a COVID-19 outbreak on our leukemia and stem cell transplantation unit (LSCT-Unit) originating from a patient with newly diagnosed acute myeloid leukemia. The patient was treated with intensive induction chemotherapy and we characterize the subsequent outbreak of COVID-19 on a LSCT-Unit. We describe the characteristics of the 36 contacts among the medical team, the results of their PCR and antibody tests and clinical aspects and features of infected employees. Of these 36 close contacts, 9 employees of the LSCT-Unit were infected and were tested positive by PCR and/or antibody-testing. 8/9 of them were symptomatic, 3/9 with severe, 5/9 with mild symptoms, and one person without symptoms. Due to stringent hygiene measures, the outbreak did not lead to infections of other patients despite ongoing clinical work. Moreover, we demonstrate that incubation period and clinical course of a COVID-19 infection in an immunosuppressed patient could be unusual compared to that of immunocompetent patients. Consistent PCR and antibody testing are helpful to understand, control, and prevent outbreaks. For the safety of health-care workers and patients alike, all employees wore FFP2 masks and were trained to adhere to several further safety guidelines. The implementation of rigorous hygiene measures is the key to controlling an outbreak and preventing infections of other patients. |
2020 |
Reiter-Owona, I; Hlobil, H; Enders, M; Klarmann-Schulz, U; Gruetzmacher, B; Rilling, V; Hoerauf, A; Garweg, J G European journal of medical research, S. 59, 2020. @article{ReiterOwona.2020, title = {Sulfadiazine plasma concentrations in women with pregnancy-acquired compared to ocular toxoplasmosis under pyrimethamine and sulfadiazine therapy: a case-control study}, author = {I Reiter-Owona and H Hlobil and M Enders and U Klarmann-Schulz and B Gruetzmacher and V Rilling and A Hoerauf and J G Garweg}, doi = {10.1186/s40001-020-00458-7}, year = {2020}, date = {2020-11-23}, journal = {European journal of medical research}, pages = {59}, abstract = {BACKGROUND Dosing recommendations for the treatment of pregnancy-acquired toxoplasmosis are empirical and widely based on experimental data. There are no pharmacological data on pregnant women with acute Toxoplasma gondii infection under treatment with pyrimethamine (PY) and sulfadiazine (SA) and our study intends to tighten this gap. METHODS In this retrospective case-control study, we included 89 pregnant women with primary Toxoplasma infection (PT) treated with PY (50~mg first dose, then 25~mg/day), SA (50~mg/kg of body weight/day), and folinic acid (10-15~mg per week). These were compared to a group of 17 women with acute ocular toxoplasmosis (OT) treated with an initial PY dose of 75~mg, thereafter 25~mg twice a day but on the same SA and folinic acid regimen. The exact interval between drug intake and blood sampling and co-medication had not been recorded. Plasma levels of PY and SA were determined 14 $pm$ 4~days after treatment initiation using liquid chromatography-mass spectrometry and compared using the Mann-Whitney U test at a p textless 0.05 level. RESULTS In 23 PT patients (26%), SA levels were below 20~mg/l. Fifteen of these 23 patients (17% of all patients) in parallel presented with PY levels below 700~µg/l. Both drug concentrations differed remarkably between individuals and groups (PY: PT median 810~µg/l, 95% CI for the median [745; 917] vs. OT 1230~µg/l [780; 1890], p = 0.006; SA: PT 46.2~mg/l [39.9; 54.4] vs. OT 70.4~mg/l [52.4; 89], p = 0.015) despite an identical SA dosing scheme. CONCLUSIONS SA plasma concentrations were found in the median 34% lower in pregnant women with PT compared to OT patients and fell below a lower reference value of 50~mg/l in a substantial portion of PT patients. The interindividual variability of plasma concentrations in combination with systematically lower drug levels and possibly a lower compliance in pregnant women may thus account for a still not yet supportable transmission risk. Systematic drug-level testing in PT under PY/SA treatment deserves to be considered.}, keywords = {}, pubstate = {published}, tppubtype = {article} } BACKGROUND Dosing recommendations for the treatment of pregnancy-acquired toxoplasmosis are empirical and widely based on experimental data. There are no pharmacological data on pregnant women with acute Toxoplasma gondii infection under treatment with pyrimethamine (PY) and sulfadiazine (SA) and our study intends to tighten this gap. METHODS In this retrospective case-control study, we included 89 pregnant women with primary Toxoplasma infection (PT) treated with PY (50~mg first dose, then 25~mg/day), SA (50~mg/kg of body weight/day), and folinic acid (10-15~mg per week). These were compared to a group of 17 women with acute ocular toxoplasmosis (OT) treated with an initial PY dose of 75~mg, thereafter 25~mg twice a day but on the same SA and folinic acid regimen. The exact interval between drug intake and blood sampling and co-medication had not been recorded. Plasma levels of PY and SA were determined 14 $pm$ 4~days after treatment initiation using liquid chromatography-mass spectrometry and compared using the Mann-Whitney U test at a p textless 0.05 level. RESULTS In 23 PT patients (26%), SA levels were below 20~mg/l. Fifteen of these 23 patients (17% of all patients) in parallel presented with PY levels below 700~µg/l. Both drug concentrations differed remarkably between individuals and groups (PY: PT median 810~µg/l, 95% CI for the median [745; 917] vs. OT 1230~µg/l [780; 1890], p = 0.006; SA: PT 46.2~mg/l [39.9; 54.4] vs. OT 70.4~mg/l [52.4; 89], p = 0.015) despite an identical SA dosing scheme. CONCLUSIONS SA plasma concentrations were found in the median 34% lower in pregnant women with PT compared to OT patients and fell below a lower reference value of 50~mg/l in a substantial portion of PT patients. The interindividual variability of plasma concentrations in combination with systematically lower drug levels and possibly a lower compliance in pregnant women may thus account for a still not yet supportable transmission risk. Systematic drug-level testing in PT under PY/SA treatment deserves to be considered. |
Schöfer, H; Enders, M; Esser, S; Feiterna-Sperling, C; Hagedorn, H-J; Magistro, G; Mayr, C; Münstermann, D; Hahn, K; Jansen, K; Klein, M; Krause, W; Maschke, M; Ochsendorf, F R; Osowski, S; Petry, K U; Potthoff, A; Rieg, S; Sing, A; Stücker, M; Weberschock, T; Werner, R N; Brockmeyer, N H Der Hautarzt, 71 (12), S. 969–999, 2020. @article{Schofer.2020, title = {Diagnostik und Therapie der Syphilis : Aktualisierung der S2k-Leitlinie 2020 der Deutsche STI-Gesellschaft (DSTIG) in Kooperation mit folgenden Fachgesellschaften: DAIG, dagn\"{a}, DDG, DGA, DGGG, DGHM, DGI, DGN, DGPI, DGU, RKI}, author = {H Sch\"{o}fer and M Enders and S Esser and C Feiterna-Sperling and H-J Hagedorn and G Magistro and C Mayr and D M\"{u}nstermann and K Hahn and K Jansen and M Klein and W Krause and M Maschke and F R Ochsendorf and S Osowski and K U Petry and A Potthoff and S Rieg and A Sing and M St\"{u}cker and T Weberschock and R N Werner and N H Brockmeyer}, doi = {10.1007/s00105-020-04672-6}, year = {2020}, date = {2020-09-17}, journal = {Der Hautarzt}, volume = {71}, number = {12}, pages = {969--999}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
Rager, A; Eggers, M; Eilts, B; Klingshirn, A Hauswirtschaft und Wissenschaft, 68 , S. 1, 2020, ISSN: 2626-0913. @article{Rager.2020, title = {Entwicklung eines neuen Bioindikatorsystems zur Pr\"{u}fung der Hygienewirkung von Geschirrsp\"{u}lverfahren unter besonderer Ber\"{u}cksichtigung von englumigem Sp\"{u}lgut}, author = {A Rager and M Eggers and B Eilts and A Klingshirn}, doi = {10.23782/HUWtextunderscore 10textunderscore 2020}, issn = {2626-0913}, year = {2020}, date = {2020-01-01}, journal = {Hauswirtschaft und Wissenschaft}, volume = {68}, pages = {1}, abstract = {Die Aufbereitung von Sp\"{u}lgut aus hygienisch sensiblen Bereichen stellt Einrichtungen wie z. B. Kindertagesst\"{a}tten und Pflegeheime vor Herausforderungen. In Einrichtungen, in denen Menschen mit noch nicht vollst\"{a}ndig ausgebildeter oder eingeschr\"{a}nkter Immunabwehr untergebracht sind, ist die Gew\"{a}hrleistung von hygienisch einwandfreiem Sp\"{u}lgut zur Vermeidung der \"{U}bertragung von Krankheitserregern sicherzustellen. Der Einsatz von Haushaltsgeschirrsp\"{u}lern in hygienisch sensiblen Bereichen wird von \"{U}berwachungsbeh\"{o}rden daher kritisch betrachtet. Mittels eines neuentwickelten Bioindikatorsystems soll die hygienische Aufbereitung von v. a. englumigem Sp\"{u}lgut in Geschirrsp\"{u}lmaschinen in diesen Einrichtungen untersucht werden.}, keywords = {}, pubstate = {published}, tppubtype = {article} } Die Aufbereitung von Spülgut aus hygienisch sensiblen Bereichen stellt Einrichtungen wie z. B. Kindertagesstätten und Pflegeheime vor Herausforderungen. In Einrichtungen, in denen Menschen mit noch nicht vollständig ausgebildeter oder eingeschränkter Immunabwehr untergebracht sind, ist die Gewährleistung von hygienisch einwandfreiem Spülgut zur Vermeidung der Übertragung von Krankheitserregern sicherzustellen. Der Einsatz von Haushaltsgeschirrspülern in hygienisch sensiblen Bereichen wird von Überwachungsbehörden daher kritisch betrachtet. Mittels eines neuentwickelten Bioindikatorsystems soll die hygienische Aufbereitung von v. a. englumigem Spülgut in Geschirrspülmaschinen in diesen Einrichtungen untersucht werden. |
Eggers, M; Benzinger, C; Suchomel, M; Hjorth, E Future microbiology, 2020. @article{Eggers.2020c, title = {Virucidal activity of three ethanol-based handrubs against murine norovirus in a hand hygiene clinical simulation study}, author = {M Eggers and C Benzinger and M Suchomel and E Hjorth}, doi = {10.2217/fmb-2020-0168}, year = {2020}, date = {2020-01-01}, journal = {Future microbiology}, abstract = {Aim: We evaluated the efficacy of three ethanol-based handrubs against murine norovirus~in a proposed clinical simulation test (prEN 17430). Materials & methods: Virucidal activity was determined in 18 volunteers using three~handrubs: ethanol 72.4~and 89.5% v/v solutions, and 86% v/v gel. Subjects underwent testing with each product (3/6~ml~for 15/30~s) and a reference solution (6~ml~70% v/v ethanol for 60~s). Results: Against murine norovirus, the reduction factors~(RF;~RF mean~$pm$ standard deviation~log10 reduction of postsampling) for ethanol gel 86% v/v (RF 1.96~$pm$~0.64), ethanol 89.5% v/v (RF 2.49~$pm$~0.59)~and ethanol 72.4% v/v (RF 2.61~$pm$~0.50), were all significantly superior to that of~the reference solution. Conclusion: All three handrubs passed the criteria set out in prEN 17430 and exhibited excellent virucidal efficacy.}, keywords = {}, pubstate = {published}, tppubtype = {article} } Aim: We evaluated the efficacy of three ethanol-based handrubs against murine norovirus~in a proposed clinical simulation test (prEN 17430). Materials & methods: Virucidal activity was determined in 18 volunteers using three~handrubs: ethanol 72.4~and 89.5% v/v solutions, and 86% v/v gel. Subjects underwent testing with each product (3/6~ml~for 15/30~s) and a reference solution (6~ml~70% v/v ethanol for 60~s). Results: Against murine norovirus, the reduction factors~(RF;~RF mean~$pm$ standard deviation~log10 reduction of postsampling) for ethanol gel 86% v/v (RF 1.96~$pm$~0.64), ethanol 89.5% v/v (RF 2.49~$pm$~0.59)~and ethanol 72.4% v/v (RF 2.61~$pm$~0.50), were all significantly superior to that of~the reference solution. Conclusion: All three handrubs passed the criteria set out in prEN 17430 and exhibited excellent virucidal efficacy. |
Stenger, T; Ledo, A; Ziller, C; Schub, D; Schmidt, T; Enders, M; Gärtner, BC; Sester, M; Meyer, T Timing of Vaccination after Training: Immune Response and Side Effects in Athletes Artikel Medicine and science in sports and exercise, 52 (7), S. 1603–1609, 2020. @article{Stenger.2020, title = {Timing of Vaccination after Training: Immune Response and Side Effects in Athletes}, author = {T Stenger and A Ledo and C Ziller and D Schub and T Schmidt and M Enders and BC G\"{a}rtner and M Sester and T Meyer}, doi = {10.1249/MSS.0000000000002278}, year = {2020}, date = {2020-01-01}, journal = {Medicine and science in sports and exercise}, volume = {52}, number = {7}, pages = {1603--1609}, abstract = {OBJECTIVES Influenza vaccination was used to assess whether induction of immunity or side effects are influenced by the timing of the last training session before vaccination. METHODS Forty-five healthy athletes (36 male, 23 $pm$ 8 yr, $geq$5 training sessions per week, predominantly national competition level) were vaccinated with the tetravalent influenza vaccine; blood samples were collected immediately before and 1, 2, and 26 wk after vaccination. Athletes were randomly assigned to vaccination within 2 h after the last training session versus after 24-26 h. Influenza-specific T cells were quantified after stimulation with the vaccine based on intracellular cytokine staining. Antibodies (IgA, IgG, IgM) were quantified by enzyme-linked immunosorbent assay and neutralization assay. Participants documented resulting side effects and training restrictions using a standardized diary. RESULTS Both groups showed an increase in influenza-reactive CD4 T-cell levels, which peaked 1 wk after vaccination (fold changes to baseline; median (interquartile range), 3.7 (3.0-5.4; P textless 0.001) in the 2-h group; 4.6 (2.8-7.4; P textless 0.001) in the 26-h group) with no difference between groups (P = 0.52). Influenza-specific antibodies showed a significant increase after vaccination in both groups (at least 1.4-fold, each P textless 0.001, no group differences; P = 0.24-0.97 for different antibody types). Only antibodies toward the Brisbane strain showed a trend toward significant differences in neutralization titers between groups (4-fold (2-17.8) in the 2-h group, 16-fold (4-32.9) in the 26-h group; P = 0.06), whereas other specificities did not differ (P = 0.16-0.72). No intergroup differences were found for side effects; no athlete reported a loss of training time due to the vaccination or its side effects. CONCLUSION Infection prophylaxis in elite athletes by influenza vaccination seems to be effective and safe. Timing of vaccination after prior training does not seem to require specific constraints.}, keywords = {}, pubstate = {published}, tppubtype = {article} } OBJECTIVES Influenza vaccination was used to assess whether induction of immunity or side effects are influenced by the timing of the last training session before vaccination. METHODS Forty-five healthy athletes (36 male, 23 $pm$ 8 yr, $geq$5 training sessions per week, predominantly national competition level) were vaccinated with the tetravalent influenza vaccine; blood samples were collected immediately before and 1, 2, and 26 wk after vaccination. Athletes were randomly assigned to vaccination within 2 h after the last training session versus after 24-26 h. Influenza-specific T cells were quantified after stimulation with the vaccine based on intracellular cytokine staining. Antibodies (IgA, IgG, IgM) were quantified by enzyme-linked immunosorbent assay and neutralization assay. Participants documented resulting side effects and training restrictions using a standardized diary. RESULTS Both groups showed an increase in influenza-reactive CD4 T-cell levels, which peaked 1 wk after vaccination (fold changes to baseline; median (interquartile range), 3.7 (3.0-5.4; P textless 0.001) in the 2-h group; 4.6 (2.8-7.4; P textless 0.001) in the 26-h group) with no difference between groups (P = 0.52). Influenza-specific antibodies showed a significant increase after vaccination in both groups (at least 1.4-fold, each P textless 0.001, no group differences; P = 0.24-0.97 for different antibody types). Only antibodies toward the Brisbane strain showed a trend toward significant differences in neutralization titers between groups (4-fold (2-17.8) in the 2-h group, 16-fold (4-32.9) in the 26-h group; P = 0.06), whereas other specificities did not differ (P = 0.16-0.72). No intergroup differences were found for side effects; no athlete reported a loss of training time due to the vaccination or its side effects. CONCLUSION Infection prophylaxis in elite athletes by influenza vaccination seems to be effective and safe. Timing of vaccination after prior training does not seem to require specific constraints. |
Russcher, A; Enders, A; de Brouwer, CS; Oepkes, D; Hahn, R; Enders, M; Kroes, AC M; Vossen, CTM A Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 129 , S. 104482, 2020. @article{Russcher.2020, title = {Diagnosis of intrauterine parvovirus B19 infection at birth - Value of DNA detection in neonatal blood and dried blood spots}, author = {A Russcher and A Enders and CS de Brouwer and D Oepkes and R Hahn and M Enders and AC M Kroes and A CTM Vossen}, doi = {10.1016/j.jcv.2020.104482}, year = {2020}, date = {2020-01-01}, journal = {Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology}, volume = {129}, pages = {104482}, abstract = {BACKGROUND Diagnosis of congenital viral infection at birth is generally attempted by direct detection of the virus by PCR in various neonatal materials. How to reliably diagnose intrauterine infection with parvovirus B19 (B19 V) at birth is unknown. OBJECTIVES To evaluate the performance of B19 V DNA detection in cord blood (CB) or neonatal dried blood spots (DBS) in diagnosing fetal infection. STUDY DESIGN Two cohorts of children diagnosed prenatally with an intrauterine B19 V infection were included in this study. CB samples of intrauterine B19 V infections that were sent to a reference laboratory for congenital infections in Stuttgart, Germany in the period 1995-2014 were tested in triplicate for B19 V DNA by quantitative PCR. DBS from children with intrauterine B19 V infection that underwent IUT at the LUMC, Leiden, the Netherlands in the period 2009-2014 were tested for B19 V DNA by quantitative B19 V PCR in triplicate. RESULTS Fourteen of twenty (70 %) CB samples tested positive for B19 V DNA. The positivity rate was 40 % (4/10) in those with a prenatal diagnosis textless20 weeks gestation. When intrauterine B19 V infection was diagnosed thereafter, 100 % (10/10) samples were B19 V DNA positive. Of the thirteen available DBS, twelve (92 %) tested positive. Viral load in CB and DBS corresponded inversely with time from fetal diagnosis to birth. CONCLUSION B19 V DNA can be detected in neonatal blood samples of children following intrauterine B19 V infection, although the possibility of false-negatives, even in severe infections, should be considered. B19 V viral load at birth correlates with timing of infection.}, keywords = {}, pubstate = {published}, tppubtype = {article} } BACKGROUND Diagnosis of congenital viral infection at birth is generally attempted by direct detection of the virus by PCR in various neonatal materials. How to reliably diagnose intrauterine infection with parvovirus B19 (B19 V) at birth is unknown. OBJECTIVES To evaluate the performance of B19 V DNA detection in cord blood (CB) or neonatal dried blood spots (DBS) in diagnosing fetal infection. STUDY DESIGN Two cohorts of children diagnosed prenatally with an intrauterine B19 V infection were included in this study. CB samples of intrauterine B19 V infections that were sent to a reference laboratory for congenital infections in Stuttgart, Germany in the period 1995-2014 were tested in triplicate for B19 V DNA by quantitative PCR. DBS from children with intrauterine B19 V infection that underwent IUT at the LUMC, Leiden, the Netherlands in the period 2009-2014 were tested for B19 V DNA by quantitative B19 V PCR in triplicate. RESULTS Fourteen of twenty (70 %) CB samples tested positive for B19 V DNA. The positivity rate was 40 % (4/10) in those with a prenatal diagnosis textless20 weeks gestation. When intrauterine B19 V infection was diagnosed thereafter, 100 % (10/10) samples were B19 V DNA positive. Of the thirteen available DBS, twelve (92 %) tested positive. Viral load in CB and DBS corresponded inversely with time from fetal diagnosis to birth. CONCLUSION B19 V DNA can be detected in neonatal blood samples of children following intrauterine B19 V infection, although the possibility of false-negatives, even in severe infections, should be considered. B19 V viral load at birth correlates with timing of infection. |
Rabenau, HF; Schwebke, I; Blümel, J; Eggers, M; Rapp, I; Steinmann, J; Willkommen, H Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 63 (5), S. 657–659, 2020, ISSN: 1436-9990. @article{Rabenau.2020b, title = {Comment on the significance, application and determination of the large volume plating (LVP) 2. Communication of the DVV/GfV Virus Disinfection Expert Committee on the DVV/RKI Guideline in the version of December 1st, 2014}, author = {HF Rabenau and I Schwebke and J Bl\"{u}mel and M Eggers and I Rapp and J Steinmann and H Willkommen}, doi = {10.1007/s00103-020-03117-8}, issn = {1436-9990}, year = {2020}, date = {2020-01-01}, journal = {Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz}, volume = {63}, number = {5}, pages = {657--659}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
Meier, T; Enders, M High reproducibility of the interferon-gamma release assay T-SPOT.TB in serial testing Artikel European journal of clinical microbiology & infectious diseases, 2020, ISSN: 0934-9723. @article{Meier.2020, title = {High reproducibility of the interferon-gamma release assay T-SPOT.TB in serial testing}, author = {T Meier and M Enders}, doi = {10.1007/s10096-020-03997-3}, issn = {0934-9723}, year = {2020}, date = {2020-01-01}, journal = {European journal of clinical microbiology & infectious diseases}, abstract = {Longitudinal studies regarding the reproducibility of Interferon-gamma release assay (IGRA) T-SPOT.TB for the diagnosis of Mycobacterium tuberculosis (M. tb) infection in serial testing are limited. We retrospectively analysed results of serially tested subjects in a medical laboratory in Germany over a time period of 14~years. From October 2004 to December 2018, a total of 5440 subjects were identified with a second T-SPOT.TB test after a median time interval of 258~days (interquartile range [IQR] 62-665). Consistently negative (n = 4520) or positive results (n = 682) were observed in 5202 (95.6%) subjects, indicating a high degree of concordance in serial testing (textgreekk = 0.83). Test conversions occurred in 101 of 4621 (2.2%) subjects with initially negative tests. Of 819 subjects with initially positive test results, 137 (16.7%) had a test reversion which was associated with low spot numbers of the first test. Of 529 subjects retested within 1~year, only 60 (11.3%) displayed a test reversion. In subjects retested after more than 1~year, 77 of 290 (26.6%) tests reverted. This significantly higher rate of test reversions after more than 1~year was age-dependent and only observed in subjects above the age of 40~years. In the medical laboratory, the T-SPOT.TB test demonstrates a high reproducibility in serial testing.}, keywords = {}, pubstate = {published}, tppubtype = {article} } Longitudinal studies regarding the reproducibility of Interferon-gamma release assay (IGRA) T-SPOT.TB for the diagnosis of Mycobacterium tuberculosis (M. tb) infection in serial testing are limited. We retrospectively analysed results of serially tested subjects in a medical laboratory in Germany over a time period of 14~years. From October 2004 to December 2018, a total of 5440 subjects were identified with a second T-SPOT.TB test after a median time interval of 258~days (interquartile range [IQR] 62-665). Consistently negative (n = 4520) or positive results (n = 682) were observed in 5202 (95.6%) subjects, indicating a high degree of concordance in serial testing (textgreekk = 0.83). Test conversions occurred in 101 of 4621 (2.2%) subjects with initially negative tests. Of 819 subjects with initially positive test results, 137 (16.7%) had a test reversion which was associated with low spot numbers of the first test. Of 529 subjects retested within 1~year, only 60 (11.3%) displayed a test reversion. In subjects retested after more than 1~year, 77 of 290 (26.6%) tests reverted. This significantly higher rate of test reversions after more than 1~year was age-dependent and only observed in subjects above the age of 40~years. In the medical laboratory, the T-SPOT.TB test demonstrates a high reproducibility in serial testing. |
Kramer, A; Eggers, M Prävention respiratorischer Virusinfektionen durch viruzide Schleimhautantiseptik bei medizinischem Personal und in der Bevölkerung Artikel Hygiene + Medizin, 45 (9), S. D118–D124, 2020, ISSN: 0172-3790. @article{Kramer.2020, title = {Pr\"{a}vention respiratorischer Virusinfektionen durch viruzide Schleimhautantiseptik bei medizinischem Personal und in der Bev\"{o}lkerung}, author = {A Kramer and M Eggers}, issn = {0172-3790}, year = {2020}, date = {2020-01-01}, journal = {Hygiene + Medizin}, volume = {45}, number = {9}, pages = {D118\textendashD124}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
Elts, B; Rager, A-M; Boursillon, D; Eggers, M Aufbereitung von Reinigungstextilien in der Krankenhausreinigung Artikel Hygiene + Medizin, 45 (7/8), S. D80–D89, 2020, ISSN: 0172-3790. @article{Elts.2020, title = {Aufbereitung von Reinigungstextilien in der Krankenhausreinigung}, author = {B Elts and A-M Rager and D Boursillon and M Eggers}, issn = {0172-3790}, year = {2020}, date = {2020-01-01}, journal = {Hygiene + Medizin}, volume = {45}, number = {7/8}, pages = {D80--D89}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
Eggers, M; Rabenau, H; Blümel, J; Fickenscher, H; Geisel, B; Glebe, D; Hengel, H; Marschang, R; Reiche, S; Steinmann, E; Steinmann, J; Schwebke, I Epidemiologisches Bulletin, (36), S. 3–14, 2020. @article{Eggers.2020b, title = {Einsatz geeigneter Desinfektionsmitteln bei gentechnisch ver\"{a}nderten Viren und viralen Vektoren -- Stellungnahme der Kommission f\"{u}r Virusdesinfektion der Deutschen Vereinigung zur Bek\"{a}mpfung der Viruskrankheiten (DVV) e. V. und der Gesellschaft f\"{u}r Virologie (GfV) e. V}, author = {M Eggers and H Rabenau and J Bl\"{u}mel and H Fickenscher and B Geisel and D Glebe and H Hengel and R Marschang and S Reiche and E Steinmann and J Steinmann and I Schwebke}, doi = {10.25646/7030}, year = {2020}, date = {2020-01-01}, journal = {Epidemiologisches Bulletin}, number = {36}, pages = {3--14}, abstract = {Im Epidemiologischen Bulletin 36/2020 haben Mitglieder der Kommission f\"{u}r Virusdesinfektion der DVV/GfV eine \"{U}bersicht h\"{a}ufig verwendeter gentechnisch ver\"{a}nderter Organismen zusammengestellt, davon ausgehend werden Aspekte der Auswahl und Anwendung von Desinfektionsmitteln n\"{a}her er\"{o}rtert. Dabei wurden neben Vertretern von Bundesoberbeh\"{o}rden, wie des FLI, des PEI und des RKI, auch Vertreter des \"{O}GD und virologischer Institute aus Universit\"{a}ten einbezogen.}, keywords = {}, pubstate = {published}, tppubtype = {article} } Im Epidemiologischen Bulletin 36/2020 haben Mitglieder der Kommission für Virusdesinfektion der DVV/GfV eine Übersicht häufig verwendeter gentechnisch veränderter Organismen zusammengestellt, davon ausgehend werden Aspekte der Auswahl und Anwendung von Desinfektionsmitteln näher erörtert. Dabei wurden neben Vertretern von Bundesoberbehörden, wie des FLI, des PEI und des RKI, auch Vertreter des ÖGD und virologischer Institute aus Universitäten einbezogen. |
Eggers, M; Hitz, DA; Elts, B Reinigung von Oberflächen - Eine mikrobiologische Untersuchung und Bewertung der Reinigung in öffentlichen Bereichen Artikel Hygiene + Medizin, 45 (7-8), S. D102–D106, 2020, ISSN: 0172-3790. @article{Eggers.2020, title = {Reinigung von Oberfl\"{a}chen - Eine mikrobiologische Untersuchung und Bewertung der Reinigung in \"{o}ffentlichen Bereichen}, author = {M Eggers and DA Hitz and B Elts}, issn = {0172-3790}, year = {2020}, date = {2020-01-01}, journal = {Hygiene + Medizin}, volume = {45}, number = {7-8}, pages = {D102--D106}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
Boursillon, D; Kocics, J; Eggers, M; Elts, B Reiniger mit Zusatz von Mikroorganismen (MARP) Artikel Hygiene + Medizin, 45 (7/8), S. 98–101, 2020, ISSN: 0172-3790. @article{Boursillon.2020, title = {Reiniger mit Zusatz von Mikroorganismen (MARP)}, author = {D Boursillon and J Kocics and M Eggers and B Elts}, issn = {0172-3790}, year = {2020}, date = {2020-01-01}, journal = {Hygiene + Medizin}, volume = {45}, number = {7/8}, pages = {98--101}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
Anderson, DE; Sivalingam, V; Kang, Eng Zheng A; Ananthanarayanan, A; Arumugam, H; Jenkins, TM; Hadjiat, Y; Eggers, M Infectious diseases and therapy, 9 (3), S. 669–675, 2020, ISSN: 2193-8229. @article{Anderson.2020, title = {Povidone-Iodine Demonstrates Rapid In Vitro Virucidal Activity Against SARS-CoV-2, The Virus Causing COVID-19 Disease}, author = {DE Anderson and V Sivalingam and A Eng Zheng Kang and A Ananthanarayanan and H Arumugam and TM Jenkins and Y Hadjiat and M Eggers}, doi = {10.1007/s40121-020-00316-3}, issn = {2193-8229}, year = {2020}, date = {2020-01-01}, journal = {Infectious diseases and therapy}, volume = {9}, number = {3}, pages = {669\textendash675}, abstract = {INTRODUCTION As of 22 June 2020, Severe Acute Respiratory Syndrome (SARS)-coronavirus (CoV)-2 has infected more than 8.95 million people worldwide, causing textgreater 468,000 deaths. The virus is transmitted through respiratory droplets and physical contact from contaminated surfaces to the mucosa. Hand hygiene and oral decontamination among other measures are key to preventing the spread of the virus. We report the in vitro virucidal activity of topical and oral povidone-iodine (PVP-I) products against SARS-CoV-2. METHODS Suspension assays were used to assess the virucidal activity of PVP-I against SARS-CoV-2. Products were tested at a contact time of 30~s for virucidal activity. Viral titres were calculated using the Spearman-K\"{a}rber method and reported as median tissue culture infectious dose (TCID50)/mL. RESULTS All four products [antiseptic solution (PVP-I 10%), skin cleanser (PVP-I 7.5%), gargle and mouth wash (PVP-I 1%) and throat spray (PVP-I 0.45%)] achieved $geq$ 99.99% virucidal activity against SARS-CoV-2, corresponding to $geq$ 4 log10 reduction of virus titre, within 30~s of contact. CONCLUSION This study provides evidence of rapid and effective virucidal activity of PVP-I against SARS-CoV-2. PVP-I-based products are widely available for medical and personal use for hand hygiene and oral decontamination, and could be readily integrated into coronavirus disease, COVID-19, infection control measures in hospital and community settings.}, keywords = {}, pubstate = {published}, tppubtype = {article} } INTRODUCTION As of 22 June 2020, Severe Acute Respiratory Syndrome (SARS)-coronavirus (CoV)-2 has infected more than 8.95 million people worldwide, causing textgreater 468,000 deaths. The virus is transmitted through respiratory droplets and physical contact from contaminated surfaces to the mucosa. Hand hygiene and oral decontamination among other measures are key to preventing the spread of the virus. We report the in vitro virucidal activity of topical and oral povidone-iodine (PVP-I) products against SARS-CoV-2. METHODS Suspension assays were used to assess the virucidal activity of PVP-I against SARS-CoV-2. Products were tested at a contact time of 30~s for virucidal activity. Viral titres were calculated using the Spearman-Kärber method and reported as median tissue culture infectious dose (TCID50)/mL. RESULTS All four products [antiseptic solution (PVP-I 10%), skin cleanser (PVP-I 7.5%), gargle and mouth wash (PVP-I 1%) and throat spray (PVP-I 0.45%)] achieved $geq$ 99.99% virucidal activity against SARS-CoV-2, corresponding to $geq$ 4 log10 reduction of virus titre, within 30~s of contact. CONCLUSION This study provides evidence of rapid and effective virucidal activity of PVP-I against SARS-CoV-2. PVP-I-based products are widely available for medical and personal use for hand hygiene and oral decontamination, and could be readily integrated into coronavirus disease, COVID-19, infection control measures in hospital and community settings. |
Munz, M; Wessendorf, S; Koretsis, G; Tewald, F; Baegi, R; Krämer, S; Geissler, M; Reinhard, M Acute transverse myelitis after COVID-19 pneumonia Artikel Journal of neurology, 267 , S. 2196-2197, 2020, ISSN: 0340-5354. @article{Munz.2020, title = {Acute transverse myelitis after COVID-19 pneumonia}, author = {M Munz and S Wessendorf and G Koretsis and F Tewald and R Baegi and S Kr\"{a}mer and M Geissler and M Reinhard}, doi = {10.1007/s00415-020-09934-w}, issn = {0340-5354}, year = {2020}, date = {2020-01-01}, journal = {Journal of neurology}, volume = {267}, pages = {2196-2197}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
Hitz, DA; Tewald, F; Eggers, M Seasonal Bordetella pertussis pattern in the period from 2008 to 2018 in Germany Artikel BMC infectious diseases, 20 (1), S. 474, 2020, ISSN: 1471-2334. @article{Hitz.2020b, title = {Seasonal Bordetella pertussis pattern in the period from 2008 to 2018 in Germany}, author = {DA Hitz and F Tewald and M Eggers}, doi = {10.1186/s12879-020-05199-w}, issn = {1471-2334}, year = {2020}, date = {2020-01-01}, journal = {BMC infectious diseases}, volume = {20}, number = {1}, pages = {474}, abstract = {BACKGROUND After the introduction of a vaccine against B. pertussis the seasonal pattern with the highest number of infections in the spring to summer months changed. Recent studies from around the world suggest that B. pertussis infections again follow a seasonal pattern with increased incidence in summer.The aim of this study was to investigate whether respiratory infections caused by B. pertussis in the period from January 2008 to December 2018 also seasonally spread in Germany and if so, when the B. pertussis activity peaked. METHODS We tested 19,031 samples, mainly from Southern Germany, collected in the period from January 2008 to December 2018 using a Multiplex PCR assay. We assessed the number and proportion of samples positive for B. pertussis, stratified by patient's age and month. The seasonal distribution was investigated by plotting the average proportion of positive samples for each month. RESULTS We observed a B. pertussis seasonality with the highest number of positive samples in the months from June until September. In contrast, testing of samples for B. pertussis was requested most frequently in the period from October until March. The proportion of positive samples increased earlier in adolescents (age 10 to 19) than in other age groups. CONCLUSIONS We found a seasonality of B. pertussis infections in Germany, which differs from the time when most samples are sent in for testing of B. pertussis. Our study suggests that clinicians should be more aware of B. pertussis infections in the months from June until September to prevent further transmission to vulnerable family members.}, keywords = {}, pubstate = {published}, tppubtype = {article} } BACKGROUND After the introduction of a vaccine against B. pertussis the seasonal pattern with the highest number of infections in the spring to summer months changed. Recent studies from around the world suggest that B. pertussis infections again follow a seasonal pattern with increased incidence in summer.The aim of this study was to investigate whether respiratory infections caused by B. pertussis in the period from January 2008 to December 2018 also seasonally spread in Germany and if so, when the B. pertussis activity peaked. METHODS We tested 19,031 samples, mainly from Southern Germany, collected in the period from January 2008 to December 2018 using a Multiplex PCR assay. We assessed the number and proportion of samples positive for B. pertussis, stratified by patient's age and month. The seasonal distribution was investigated by plotting the average proportion of positive samples for each month. RESULTS We observed a B. pertussis seasonality with the highest number of positive samples in the months from June until September. In contrast, testing of samples for B. pertussis was requested most frequently in the period from October until March. The proportion of positive samples increased earlier in adolescents (age 10 to 19) than in other age groups. CONCLUSIONS We found a seasonality of B. pertussis infections in Germany, which differs from the time when most samples are sent in for testing of B. pertussis. Our study suggests that clinicians should be more aware of B. pertussis infections in the months from June until September to prevent further transmission to vulnerable family members. |
Hübner, N-O; Eggers, M; Schwebke, I; Suchomel, M Händedesinfektion unter den Bedingungen der SARSCoV- 2-Pandemie Artikel Epidemiologisches Bulletin, 19 , S. 13-19, 2020. @article{Hubner.2020, title = {H\"{a}ndedesinfektion unter den Bedingungen der SARSCoV- 2-Pandemie}, author = {N-O H\"{u}bner and M Eggers and I Schwebke and M Suchomel}, url = {https://edoc.rki.de/handle/176904/6774?show=full}, doi = {10.25646/6861}, year = {2020}, date = {2020-01-01}, journal = {Epidemiologisches Bulletin}, volume = {19}, pages = {13-19}, abstract = {Die aktuelle SARS-CoV-2-Pandemie f\"{u}hrt uns zum einen den Stellenwert der H\"{a}ndedesinfektion zum Schutz der Patienten und Besch\"{a}ftigten vor Augen. Zum anderen zeigt sie, wie wichtig die stete Verf\"{u}gbarkeit von H\"{a}ndedesinfektionsmitteln ist, deren Wirksamkeit, Qualit\"{a}t und Unbedenklichkeit nachgewiesen und die unter praktischen Bedingungen tauglich sind. Aussagen u. a. zu Bestandteilen, zur Deklaration der Wirksamkeit und zur Qualit\"{a}t von alkoholischen H\"{a}ndedesinfektionsmitteln werden im Epidemiologischen Bulletin 19/2020 n\"{a}her ausgef\"{u}hrt.}, keywords = {}, pubstate = {published}, tppubtype = {article} } Die aktuelle SARS-CoV-2-Pandemie führt uns zum einen den Stellenwert der Händedesinfektion zum Schutz der Patienten und Beschäftigten vor Augen. Zum anderen zeigt sie, wie wichtig die stete Verfügbarkeit von Händedesinfektionsmitteln ist, deren Wirksamkeit, Qualität und Unbedenklichkeit nachgewiesen und die unter praktischen Bedingungen tauglich sind. Aussagen u. a. zu Bestandteilen, zur Deklaration der Wirksamkeit und zur Qualität von alkoholischen Händedesinfektionsmitteln werden im Epidemiologischen Bulletin 19/2020 näher ausgeführt. |
Hitz, D; Exler, S; Daiminger, A; Bartelt, U; Enders, M Low-level positive results in the Liaison CMV IgG II assay may misclassify pregnant woman as immune Artikel Diagnostic microbiology and infectious disease, S. 115029, 2020. @article{Hitz.2020, title = {Low-level positive results in the Liaison CMV IgG II assay may misclassify pregnant woman as immune}, author = {D Hitz and S Exler and A Daiminger and U Bartelt and M Enders}, doi = {10.1016/j.diagmicrobio.2020.115029}, year = {2020}, date = {2020-01-01}, journal = {Diagnostic microbiology and infectious disease}, pages = {115029}, abstract = {The aim of this study is to report on the specificity in the low-positive range of the Liaison CMV IgG II assay for determination of cytomegalovirus immune status in pregnancy. Sera with test results between 12.0 and 40.0 U/mL were retested with the Enzygnost Anti-CMV/IgG assay. Enzygnost-negative samples were analyzed by the Serion ELISA classic Cytomegalovirus IgG assay and, if positive or equivocal, also with the Mikrogen recomLine CMV IgG assay. A total of 12,117 sera were tested with the Liaison assay. Sixty sera were equivocal (12.0-13.9 U/mL), and 400 of 4295 positive sera were low-positive (14.0-40.0 U/mL). Based on consensus, at least 14% of the low-positives and 1.3% of all Liaison-positives can be considered as misclassified. The proportion of misclassified sera increased with lower Liaison IgG results. We suggest that the range for equivocal results in the Liaison assay should be revised.}, keywords = {}, pubstate = {published}, tppubtype = {article} } The aim of this study is to report on the specificity in the low-positive range of the Liaison CMV IgG II assay for determination of cytomegalovirus immune status in pregnancy. Sera with test results between 12.0 and 40.0 U/mL were retested with the Enzygnost Anti-CMV/IgG assay. Enzygnost-negative samples were analyzed by the Serion ELISA classic Cytomegalovirus IgG assay and, if positive or equivocal, also with the Mikrogen recomLine CMV IgG assay. A total of 12,117 sera were tested with the Liaison assay. Sixty sera were equivocal (12.0-13.9 U/mL), and 400 of 4295 positive sera were low-positive (14.0-40.0 U/mL). Based on consensus, at least 14% of the low-positives and 1.3% of all Liaison-positives can be considered as misclassified. The proportion of misclassified sera increased with lower Liaison IgG results. We suggest that the range for equivocal results in the Liaison assay should be revised. |
Rabenau, HF; Schwebke, I; Blümel, J; Eggers, M; Glebe, D; Rapp, I; Sauerbrei, A; Steinmann, E; Steinmann, J; Willkommen, He; Wutzler, P Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 63 (5), S. 645–655, 2020, ISSN: 1436-9990. @article{Rabenau.2020, title = {Guideline for testing chemical disinfectants regarding their virucidal activity within the field of human medicine : as of December 1st, 2014 Prepared by the German Association for the Control of Virus Diseases (DVV) and the Robert Koch Institute (RKI)}, author = {HF Rabenau and I Schwebke and J Bl\"{u}mel and M Eggers and D Glebe and I Rapp and A Sauerbrei and E Steinmann and J Steinmann and He Willkommen and P Wutzler}, doi = {10.1007/s00103-020-03115-w}, issn = {1436-9990}, year = {2020}, date = {2020-01-01}, journal = {Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz}, volume = {63}, number = {5}, pages = {645--655}, keywords = {}, pubstate = {published}, tppubtype = {article} } |
Ledo, A; Schub, D; Ziller, C; Enders, M; Stenger, T; Gärtner, BC; Schmidt, T; Meyer, T; Sester, M Brain, behavior, and immunity, 83 , S. 135-145, 2020. @article{Ledo.2020, title = {Elite athletes on regular training show more pronounced induction of vaccine-specific T-cells and antibodies after tetravalent influenza vaccination than controls}, author = {A Ledo and D Schub and C Ziller and M Enders and T Stenger and BC G\"{a}rtner and T Schmidt and T Meyer and M Sester}, doi = {10.1016/j.bbi.2019.09.024}, year = {2020}, date = {2020-01-01}, journal = {Brain, behavior, and immunity}, volume = {83}, pages = {135-145}, abstract = {Compliance of elite athletes with vaccination recommendations is low mainly based on concerns about side-effects and perceived poor vaccine efficacy due to continued physical training. We therefore employed seasonal influenza vaccination to investigate the effect of regular physical training on vaccine-induced cellular and humoral immunity in elite athletes and controls. Lymphocyte subpopulations and vaccine-specific T-cells were quantified and functionally characterized from 45 athletes and 25 controls before, and 1, 2 and 26 weeks after vaccination. Moreover, influenza-specific antibodies and their neutralizing function were quantified. Both groups showed a significant increase in vaccine-reactive CD4 T-cell levels which peaked one week after vaccination (p textless 0.0001). The increase was significantly more pronounced in athletes (4.1-fold) compared to controls (2.3-fold; p = 0.0007). The cytokine profile changed from multifunctional T-cells co-producing IFNtextgreekg, IL-2 and TNFtextgree\k{a} to cells with restricted cytokine expression. This change in functionality was associated with a significant increase in CTLA-4 expression (p textless 0.0001), which again was more pronounced in athletes. Likewise, the increase in neutralizing antibodies was stronger in athletes (p = 0.004 for H1N1; p = 0.032 for H3N2). In conclusion, both groups mounted a strong vaccine-specific cellular and humoral immunity after standard vaccination. The more pronounced increase in specific T-cells and neutralizing antibodies indicates that high frequency and intensity of training enhance vaccine-responses in elite athletes.}, keywords = {}, pubstate = {published}, tppubtype = {article} } Compliance of elite athletes with vaccination recommendations is low mainly based on concerns about side-effects and perceived poor vaccine efficacy due to continued physical training. We therefore employed seasonal influenza vaccination to investigate the effect of regular physical training on vaccine-induced cellular and humoral immunity in elite athletes and controls. Lymphocyte subpopulations and vaccine-specific T-cells were quantified and functionally characterized from 45 athletes and 25 controls before, and 1, 2 and 26 weeks after vaccination. Moreover, influenza-specific antibodies and their neutralizing function were quantified. Both groups showed a significant increase in vaccine-reactive CD4 T-cell levels which peaked one week after vaccination (p textless 0.0001). The increase was significantly more pronounced in athletes (4.1-fold) compared to controls (2.3-fold; p = 0.0007). The cytokine profile changed from multifunctional T-cells co-producing IFNtextgreekg, IL-2 and TNFtextgreeą to cells with restricted cytokine expression. This change in functionality was associated with a significant increase in CTLA-4 expression (p textless 0.0001), which again was more pronounced in athletes. Likewise, the increase in neutralizing antibodies was stronger in athletes (p = 0.004 for H1N1; p = 0.032 for H3N2). In conclusion, both groups mounted a strong vaccine-specific cellular and humoral immunity after standard vaccination. The more pronounced increase in specific T-cells and neutralizing antibodies indicates that high frequency and intensity of training enhance vaccine-responses in elite athletes. |
2019 |
Kohmer, N; Nagel, A; Berger, A; Enders, M; Hamprecht, K; Korn, K; Kortenbusch, M; Überla, K; Rabenau, H F Laboratory diagnosis of congenital CMV infection in newborns: Impact of pre-analytic factors Artikel Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 115 , S. 32–36, 2019, ISSN: 1386-6532. @article{Kohmer.2019, title = {Laboratory diagnosis of congenital CMV infection in newborns: Impact of pre-analytic factors}, author = {N Kohmer and A Nagel and A Berger and M Enders and K Hamprecht and K Korn and M Kortenbusch and K \"{U}berla and H F Rabenau}, doi = {10.1016/j.jcv.2019.03.017}, issn = {1386-6532}, year = {2019}, date = {2019-01-01}, journal = {Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology}, volume = {115}, pages = {32--36}, abstract = {BACKGROUND To identify infants with congenital cytomegalovirus (cCMV) saliva polymerase chain reaction (PCR) is an ideal screening method. However, there are only few data on the influence of pre-analytic factors on the analytical sensitivity of the CMV PCR. OBJECTIVES This study aimed to evaluate the performance of different swabbing materials, transport time and initial virus concentration regarding to the efficacy of recovery of CMV-DNA. STUDY DESIGN Two CMV suspensions containing a high or low concentration of the laboratory strain AD 169 were prepared as test samples. Sampling was simulated by immersion of different swabs in these CMV suspensions and storing the swabs dry or in specified transport media. Transport conditions were modeled by storing the samples for defined time periods prior to DNA extraction and quantitative PCR analyses. Parallel analyses in two different laboratories allowed determination of lab to lab consistency. RESULTS The duration of storage under the conditions analysed did not have a major effect on the recovery efficiency for the swabbing materials tested. With exception of flocked dry swabs, all tested swabbing materials demonstrated good recovery of CMV DNA. The flocked swab/eNAT system showed the best overall performance. CONCLUSIONS All tested swabbing materials (with exception of the flocked dry swabs) seem to be well suited for recovery of CMV DNA and appropriate for use for the diagnosis of cCMV infection in symptomatic cases and in general cCMV screening programs of newborns.}, keywords = {}, pubstate = {published}, tppubtype = {article} } BACKGROUND To identify infants with congenital cytomegalovirus (cCMV) saliva polymerase chain reaction (PCR) is an ideal screening method. However, there are only few data on the influence of pre-analytic factors on the analytical sensitivity of the CMV PCR. OBJECTIVES This study aimed to evaluate the performance of different swabbing materials, transport time and initial virus concentration regarding to the efficacy of recovery of CMV-DNA. STUDY DESIGN Two CMV suspensions containing a high or low concentration of the laboratory strain AD 169 were prepared as test samples. Sampling was simulated by immersion of different swabs in these CMV suspensions and storing the swabs dry or in specified transport media. Transport conditions were modeled by storing the samples for defined time periods prior to DNA extraction and quantitative PCR analyses. Parallel analyses in two different laboratories allowed determination of lab to lab consistency. RESULTS The duration of storage under the conditions analysed did not have a major effect on the recovery efficiency for the swabbing materials tested. With exception of flocked dry swabs, all tested swabbing materials demonstrated good recovery of CMV DNA. The flocked swab/eNAT system showed the best overall performance. CONCLUSIONS All tested swabbing materials (with exception of the flocked dry swabs) seem to be well suited for recovery of CMV DNA and appropriate for use for the diagnosis of cCMV infection in symptomatic cases and in general cCMV screening programs of newborns. |